- Conditions
- Healthy
- Interventions
- Samidorphan IV, [14c]-Samidorphan sublingual, [14c]-Samidorphan oral
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 102
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- ALKS 3831, Olanzapine
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 52
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 46 more
- Conditions
- Bipolar I Disorder, Schizophrenia
- Interventions
- OLZ/SAM
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Stanford, California + 12 more
- Conditions
- Healthy
- Interventions
- Moxifloxacin, ALKS 5461, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole Lauroxil, Computerized cognitive and functional skills training
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Opiate Dependence
- Interventions
- Extended-Release Naltrexone, Motivational Enhancement Counseling
- Drug · Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Human Insulin Inhalation Powder, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 24
- States / cities
- Fresno, California • Pomona, California • West Palm Beach, Florida + 21 more
- Conditions
- Alcohol Dependence
- Interventions
- RDC-0313, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Spartanburg, South Carolina
- Conditions
- Binge Eating Disorder
- Interventions
- RDC-0313 (ALKS 33), Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Minneapolis, Minnesota • Manlius, New York + 3 more
- Conditions
- Major Depressive Disorder
- Interventions
- ALKS 5461, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Oceanside, California • Santa Ana, California + 24 more
- Conditions
- Schizophrenia
- Interventions
- TES-TI, Sham TES-TI
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Schizophrenia, Bipolar I Disorder
- Interventions
- OLZ/SAM, Olanzapine
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 26
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Encino, California + 23 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Human Insulin Inhalation Powder, Injectable insulin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 9
- States / cities
- Sacramento, California • Santa Ana, California • Jacksonville, Florida + 6 more
- Conditions
- Opiate Dependence
- Interventions
- Medisorb naltrexone 380 mg
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Colton, California • Oceanside, California • Lauderhill, Florida + 7 more
- Conditions
- Cocaine Dependence, Alcohol Dependence
- Interventions
- VIVITROL (Naltrexone extended-release injectable suspension), Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole Lauroxil
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 14 more
- Conditions
- Major Depressive Disorder
- Interventions
- ALKS 5461, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 50
- States / cities
- Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 45 more
- Conditions
- Opioid Use Disorders
- Interventions
- XR-NTX, XR-NTX+PN, ETAU
- Drug · Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Amphetamine-Related Disorders
- Interventions
- Naltrexone, Placebo
- Drug
- Lead sponsor
- San Francisco Department of Public Health
- Government
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Focus of Study is on Healthy Lactating Women
- Interventions
- LYBALVI
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Substance-Related Disorders
- Interventions
- naltrexone for extended release injectable suspension
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Opioid-Related Disorders
- Interventions
- Naltrexone for extended-release injectable suspension, Oral naltrexone
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
- Interventions
- ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 786 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 34
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more